September 27th 2024
Dr. Xiuning Le highlights real-world data on therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations, emphasizing the need for improved treatments, at ESMO Congress 2024.
September 10th 2024
Xiuning Le, MD, PhD, discusses updated findings from the phase 1/2 SOHO-01 trial.
October 28th 2023
Xiuning Le, MD, PhD, discusses findings from the interim analysis of the phase 2 RAMOSE trial in patients with TKI-naïve metastatic non–small cell lung cancer harboring EGFR mutations.
August 29th 2023
Xiuning Le, MD, PhD, discusses ongoing and future investigations with osimertinib and chemotherapy in patients with metastatic lung cancer.
November 15th 2021
Xiuning Le, MD, PhD, discusses the emergence of antibody-drug conjugates in non–small cell lung cancer.
May 12th 2021
Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.
April 10th 2021
Xiuning Le, MD, PhD, discusses the safety findings of the phase 2 ZENITH20-5 study with poziotinib in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.
July 13th 2020
Xiuning Le, MD, PhD, discusses the design of the phase 2 VISION trial in MET exon 14 skipping—mutant non–small cell lung cancer.
June 9th 2020
Xiuning Le, MD, PhD, discusses the rationale for tepotinib in MET exon 14 skipping